HIMA/FDA meeting
This article was originally published in The Gray Sheet
Executive Summary
The board of the Health Industry Manufacturers Association met with members of the Center for Devices and Radiological Health Dec. 8 in Washington, D.C. Representatives of the device center included Director Bruce Burlington, Deputy Director for Regulation and Policy Joseph Levitt, Deputy Director for Science Elizabeth Jacobsen, and Director of the Office of Device Evaluation Susan Alpert, according to HIMA staffers. During the meeting, HIMA President Alan Magazine articulated the association's position that there are fundamental problems with the philosophy at CDRH that need to be addressed, including the center's intrusion into the practice of medicine, law enforcement mentality, and adversarial attitude toward the U.S. device industry
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.